Literature DB >> 17171649

Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent.

Michael Schoppet1, Stephanie Henser, Volker Ruppert, Thomas Stübig, Nadia Al-Fakhri, Bernhard Maisch, Lorenz C Hofbauer.   

Abstract

Dendritic cells (DC) comprise a unique leukocyte population which controls primary immune responses. Recent studies indicate that DC express osteoprotegerin (OPG), a secreted tumor necrosis factor receptor homolog, which regulates DC survival, monocyte chemotaxis, and B cell development and function by ligating TNF family member receptor activator of NF-kappaB ligand (RANKL). The precise regulators of OPG expression in DC have not been investigated. In this study, we assessed OPG mRNA steady state levels by Northern blot analysis and OPG protein secretion by an immunoassay in monocyte-derived DC of different maturation, and the effect of different cytokines and hormones on OPG expression. OPG was upregulated with maturation of DC, whereas pretreatment of DC with 1alpha,25(OH)(2) vitamin D(3), tamoxifen, or dexamethasone, agents that inhibit differentiation of DC, decreased OPG expression. In vivo, OPG was found to be colocalized with mature CD83(+) DC in human tonsils by immunofluorescence confocal microscopy analysis. Furthermore, OPG was upregulated by TNF superfamily members TNF-alpha, anti-CD40, and RANKL, and by ligands of the Toll-like/IL-1 receptor family including IL-1beta, double-stranded RNA (poly I:C), or lipopolysaccharide (LPS), all of which induce maturation of DC. Gene silencing by small interfering RNA (siRNA) directed against transcription factor NF-kappaB abrogated the expression of OPG as demonstrated by real-time PCR. In summary, we describe that the expression of OPG by DC increases with maturation and is NF-kappaB-dependent, possibly regulating immune responses in lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17171649     DOI: 10.1002/jcb.21129

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  16 in total

1.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

2.  Predictive Value of Osteoprotegerin and Neutrophil Gelatinase-associated Lipocalin on Multiple Organ Failure in Multiple Trauma.

Authors:  Henning Peters; Christian Macke; Philipp Mommsen; Christian Zeckey; Jan-Dierk Clausen; Christian Krettek; Claudia Neunaber; Marcel Winkelmann
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

3.  Serum osteoprotegerin is markedly increased and may contribute to decreased blood T cell count in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Efi Yiannaki; Vassilios Liakopoulos; Georgia Antoniadi; Georgios Pissas; Grammati Galaktidou; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2013-01-08       Impact factor: 2.370

4.  Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.

Authors:  Srinivas Koduru; Ellice Wong; Till Strowig; Ranjini Sundaram; Lin Zhang; Matthew P Strout; Richard A Flavell; David G Schatz; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.

Authors:  Seth G Thacker; Celine C Berthier; Deborah Mattinzoli; Maria Pia Rastaldi; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

Review 6.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

7.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

8.  NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.

Authors:  Antonios O Aliprantis; Yasuyoshi Ueki; Rosalyn Sulyanto; Arnold Park; Kirsten S Sigrist; Sudarshana M Sharma; Michael C Ostrowski; Bjorn R Olsen; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2008-10-09       Impact factor: 14.808

9.  Emerging Functions of RANKL in Lymphoid Tissues.

Authors:  Christopher G Mueller; Estelle Hess
Journal:  Front Immunol       Date:  2012-09-03       Impact factor: 7.561

10.  Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Authors:  Sebastian Meltzer; Erta Kalanxhi; Helga Helseth Hektoen; Svein Dueland; Kjersti Flatmark; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.